Paul Tudor Jones Taysha Gene Therapies, Inc. Transaction History
Tudor Investment Corp Et Al
- $19.2 Billion
- Q2 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 26,634 shares of TSHA stock, worth $55,132. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,634Holding current value
$55,132% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding TSHA
# of Institutions
107Shares Held
136MCall Options Held
65.4KPut Options Held
41.7K-
Rtw Investments, LP New York, NY18.8MShares$38.9 Million0.7% of portfolio
-
Avoro Capital Advisors LLC New York, NY18.7MShares$38.6 Million0.57% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$24.3 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$22.5 Million0.37% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$18.6 Million2.21% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $100M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...